This cluster groups 2 independently calculated changes: Cash & equivalents decreased 96.8%; Operating cash flow decreased 68.6%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTApimeds Pharmaceuticals US, Inc.'s latest supported as-filed period reports net income of -$20.2M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 96.8%; Operating cash flow decreased 68.6%.
2 evidence-backed componentsOperating income changed -135.7% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
APUS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-099002SEC ↗8-KAug 21, 2026Period Aug 19, 20260001213900-26-092680SEC ↗10-QAug 14, 2026Period Jun 30, 20260001213900-26-090120SEC ↗8-KAug 6, 2026Period Aug 5, 20260001213900-26-086244SEC ↗8-KJul 13, 2026Period Jul 13, 20260001213900-26-077591SEC ↗10-QMay 26, 2026Period Mar 31, 20260001213900-26-061013SEC ↗8-KMay 5, 2026Period May 5, 20260001213900-26-052036SEC ↗GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed -68.6% from the comparable as-filed period.
Shares outstanding changed -88.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current ratio changed -96.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital / assets changed -9861 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed +47.2% from the comparable as-filed period.
Cash & equivalents changed -96.8% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-051139